Potassium Citrate
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
- Potassium Citrate
- Potassium Citrate: From an Undocumented Original Indication to Familial Visceral Myopathy
Potassium Citrate: From an Undocumented Original Indication to Familial Visceral Myopathy
One-Sentence Summary
No approved original indication is on file for potassium citrate in this evidence pack, and the drug is currently not marketed in New Zealand. The TxGNN model predicts it may be effective for Familial Visceral Myopathy, but this is currently a model-only prediction — no clinical trials or publications have been identified that support this specific indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented (no approved indication on file for this product) |
| Predicted New Indication | Familial visceral myopathy |
| TxGNN Prediction Score | 99.95% |
| Evidence Level | L5 |
| New Zealand Market Status | Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for potassium citrate in this evidence pack, and no original approved indication is on file, which limits mechanistic-link analysis for this predicted indication.
Separately, the evidence pack shows that potassium citrate is well characterized in the literature as a urinary alkalinizing agent used to raise urine pH and citrate levels for kidney stone prevention (see the nephrolithiasis evidence below). However, no mechanistic rationale connecting this pharmacology to familial visceral myopathy — a rare gastrointestinal motility disorder — has been retrieved to date. The high TxGNN score (rank 771 of the model's output) reflects a learned graph association rather than an established or hypothesized biological pathway at this time.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
New Zealand Market Information
Potassium citrate currently holds no product licenses in New Zealand (market status: Not Marketed; total authorizations: 0).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN score for familial visceral myopathy is high, but there is zero clinical trial or published literature evidence linking potassium citrate to this indication, and a blocking data gap (missing TFDA-equivalent package insert warnings/contraindications) prevents even a preliminary safety assessment.
To proceed, the following is needed:
- Package insert warnings and contraindications (currently a blocking gap for safety review)
- Mechanism of action (MOA) data for potassium citrate
- A targeted literature/clinical trial search specifically on citrate/potassium pathways in visceral myopathy or related GI motility disorders
- Documentation of the drug's original approved indication(s), which is currently absent from this evidence pack
- For comparison: rank 4 in this evidence pack (nephrolithiasis) has 36 clinical trials and 19 publications and may represent a more actionable near-term repurposing candidate than this rank-1 prediction
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.